A mouse study reveals a connection between dementia risk and cold frequency.

Published Date: 05 Apr 2023

Being ill frequently may slow down brain aging and raise the risk of dementia and other forms of cognitive decline.

Read Full News

Latest News

NeuroVoices: Robert Alexander, MD, on the Evolution of Antiamyloid Therapeutics in Alzheimer Disease Robert Alexander, MD, Isabella Ciccone, MPH

At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

Autologous Stem Cell Approach Shows Promising Early Phase 1 Data in Alzheimer Disease Marco Meglio

A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.

New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease Isabella Ciccone, MPH

In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.

CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease Marco Meglio

Semaglutide shows no significant impact on Alzheimer disease progression in large trials, despite some biomarker improvements and consistent safety profiles.

Neflamapimod Reduces Plasma GFAP in Dementia With Lewy Bodies, Showing Correlation With Clinical Improvement Marco Meglio

New data highlights neflamapimod's potential in reducing biomarkers and improving clinical outcomes for dementia with Lewy bodies, paving the way for Phase 3 trials.

Alzheimer Vaccine ABvac40 Results in Lowered Cortical Perfusion Decline Marco Meglio

A recent study reveals that Araclon's ABvac40 vaccine may slow cortical perfusion decline in patients with Alzheimer disease, suggesting potential cognitive benefits.

Todays Updates

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Todays Updates

Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results Louie Pasculli

Merck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.

Dravet Syndrome Medication Stiripentol Effective in Real World Settings Across Various Patient Profiles Marco Meglio

New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.

NBI-827104’s Phase 2 Disappointment Highlight Therapeutic Needs for Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Marco Meglio

New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Latest News

At CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.

A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.

In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.

Semaglutide shows no significant impact on Alzheimer disease progression in large trials, despite some biomarker improvements and consistent safety profiles.

New data highlights neflamapimod's potential in reducing biomarkers and improving clinical outcomes for dementia with Lewy bodies, paving the way for Phase 3 trials.

A recent study reveals that Araclon's ABvac40 vaccine may slow cortical perfusion decline in patients with Alzheimer disease, suggesting potential cognitive benefits.

News All Time

NeurologyLive® Friday 5 — November 28, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

Episode 155: Understanding Variability in Infantile Spasms Care Marco Meglio, Christina Briscoe, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Standalone Traumatic Brain Injuries Rarely Lead to Chronic Traumatic Encephalopathy Development Enna Selmanovic, Louie Pasculli

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome Marco Meglio

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease Marco Meglio

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Isabella Ciccone, MPH

Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

Natalizumab Biosimilar Officially Launched in the United States Marco Meglio

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy Marco Meglio

The FDA has approved Novartis’ intrathecal formulation of onasemnogene abeparvovec-brve, marketed as Itvisma, for patients ages 2 years and older living with spinal muscular atrophy.

Study Identifies Environmental Risk Factors Significantly Associated With Neuromyelitis Optica Spectrum Disorder Isabella Ciccone, MPH

Findings revealed that vitamin D deficiency was associated with an increased risk of NMOSD in East Asian populations, whereas the effect of smoking among Caucasians and other populations was inconsistent.

Advancing DM1 and DMD Care: Insights on DYNE-101 and DYNE-251 Development Marco Meglio

Doug Kerr, MD, PhD, chief medical officer at Dyne Therapeutics, discusses the clinical development of DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy.

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Recommended News For You

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

Long-term study links chronic conditions in midlife to higher cancer risk and mortality

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

A novel blood test may enable the early identification of common, fatal cancers.

Study links persistent fatigue in breast cancer survivors to increased inflammation

examining differences in the rates of breast reconstruction following mastectomies.

Recommended Articles For You

Breaking Down Leukocytoclastic Vasculitis: Causes, Symptoms and Treatment 

The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting  

A Closer Look at the Effects of Sickle Cell on Eyesight 

The Journey Beyond Treatment: Empowering Cancer Survivorship with Technology and Artificial Intelligence 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Emicizumab in Infants With Hemophilia A: Safe and Effective Use.

2.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

3.

More People Than Previously Believed Have Schizophrenia.

4.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.

5.

Is Laughter Good for Blood Glucose Control?

1.

Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models

2.

Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support

3.

Exploring the Causes and Treatments of Bacterial Keratitis: A Comprehensive Guide

4.

A Visual Journey Through Penile Cancer: Examining the Impact of Photos

5.

Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

2.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management

3.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot